New treatment could free type-1 diabetics from 'daily grind' of insulin injections

Researchers hail findings as a possible 'game-changer' and 'a new way forward' for patients

Ian Johnston
Thursday 26 November 2015 00:57 GMT
Comments
An injection of insulin is administered. File photo
An injection of insulin is administered. File photo (Getty Images)

Hundreds of thousands of diabetics could potentially be freed from the “daily grind” of insulin injections after research suggested a new treatment was safe.

Scientists at the University of California, San Francisco, developed a way of restoring the ability of people with type-1 diabetes to produce insulin for a year or more using their own immune cells, The Times newspaper reported.

A type-1 diabetic’s immune system attacks the pancreas but the researchers cultivated billions of T-regulatory immune cells, known as Tregs, that do not have this trait and gave them to the patients.

Professor Jeffrey Bluestone, one of the scientists involved in the work, said their findings could be a “game-changer”.

“For type-1 diabetes, we’ve traditionally given immunosuppressive drugs, but this trial gives us a new way forward,” he said.

“By using Tregs to re-educate the immune system, we may be able to change the course of this disease.”

In the first clinical trial of the technique, 14 people were treated without any serious side-effects, the researchers reported in the journal, Science Translation Medicine. They now plan a larger trial.

The method involves taking a pint of blood from the patient, removing up to 4 million Tregs and then increasing that number by 1,500 times in a test tube.

They are then returned to the patient and do not attack the pancreas. Up to 25 per cent were found to be still there after 12 months.

The procedure could potentially be used to treat other conditions such as rheumatoid arthritis, cardiovascular disease and even obesity.

“Using a patient’s own cells - identifying them, isolating them, expanding them, and infusing them back - is an exciting new pillar for drug development,” Professor Bluestone said.

One of the patients in the trial, Mary Rooney, 39, said: “The work of Dr Bluestone and his team offers new hope for people with type-1 diabetes.

“The Treg intervention aims to prevent the development and progression of type-1 diabetes, freeing people like me from the daily grind of insulin therapy and lifelong fear of complications.”

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in